IL178689A0 - Pharmaceutical solution formulations containing 17-aag - Google Patents

Pharmaceutical solution formulations containing 17-aag

Info

Publication number
IL178689A0
IL178689A0 IL178689A IL17868906A IL178689A0 IL 178689 A0 IL178689 A0 IL 178689A0 IL 178689 A IL178689 A IL 178689A IL 17868906 A IL17868906 A IL 17868906A IL 178689 A0 IL178689 A0 IL 178689A0
Authority
IL
Israel
Prior art keywords
aag
formulations containing
pharmaceutical solution
solution formulations
pharmaceutical
Prior art date
Application number
IL178689A
Other languages
English (en)
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of IL178689A0 publication Critical patent/IL178689A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL178689A 2004-05-11 2006-10-17 Pharmaceutical solution formulations containing 17-aag IL178689A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57021504P 2004-05-11 2004-05-11
US11/123,570 US20050256097A1 (en) 2004-05-11 2005-05-05 Pharmaceutical solution formulations containing 17-AAG
PCT/US2005/016010 WO2005110398A2 (en) 2004-05-11 2005-05-06 Pharmaceutical solution formulations containing 17-aag

Publications (1)

Publication Number Publication Date
IL178689A0 true IL178689A0 (en) 2007-02-11

Family

ID=35310196

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178689A IL178689A0 (en) 2004-05-11 2006-10-17 Pharmaceutical solution formulations containing 17-aag

Country Status (10)

Country Link
US (1) US20050256097A1 (enExample)
EP (1) EP1744743A2 (enExample)
JP (1) JP2007537258A (enExample)
AU (1) AU2005244115A1 (enExample)
BR (1) BRPI0511036A (enExample)
CA (1) CA2565583A1 (enExample)
IL (1) IL178689A0 (enExample)
MX (1) MXPA06012935A (enExample)
RU (1) RU2382643C2 (enExample)
WO (1) WO2005110398A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
WO2006119032A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
KR20080000682A (ko) * 2005-04-29 2008-01-02 코산 바이오사이언시즈, 인코포레이티드 17-ａａｇ 또는 17-ａｇ, 또는 이들의 프로드럭을 사용한다발성 골수종의 치료 방법
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
WO2008055386A1 (fr) * 2006-11-10 2008-05-15 Shenzhen Shengeryimei Biotech Co., Ltd. Composition pharmaceutique hydrosoluble pour injection de 17-allyl amino-17-déméthoxy geldanamycine (17-aag)
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
JP2010516282A (ja) * 2007-01-26 2010-05-20 コーサン バイオサイエンシーズ， インコーポレイテッド 工学的生合成によるマクロラクタム
JP2010533180A (ja) * 2007-07-09 2010-10-21 グレン エス． クウォン， 治療剤
MX2010003774A (es) * 2007-10-08 2010-04-27 Fovea Pharmaceuticals Sa Formulaciones oftalmicas acuosas.
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
WO2010032140A2 (en) 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
US8236329B2 (en) * 2009-09-25 2012-08-07 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
WO2011116286A2 (en) * 2010-03-18 2011-09-22 Innopharma, Llc Stable bortezomib formulations
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016094831A1 (en) * 2014-12-11 2016-06-16 University Of Utah Research Foundation Bi-functional allosteric protein-drug molecules for targeted therapy
FI3253401T3 (fi) 2015-02-03 2025-07-09 Amryt Endo Inc Akromegallian hoitaminen suun kautta annettavalla oktreotidilla
JP2018008922A (ja) * 2015-08-04 2018-01-18 わかもと製薬株式会社 ステロイド白内障の予防及び治療
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US553153A (en) * 1896-01-14 Type-writing machine
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5932556A (en) * 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
ATE554750T1 (de) * 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
US6121323A (en) * 1997-12-03 2000-09-19 3M Innovative Properties Company Bishydroxyureas
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
JP2002532535A (ja) * 1998-12-22 2002-10-02 アメリカ合衆国 水不溶性薬剤送達システム
TW471968B (en) * 1999-08-25 2002-01-11 Committee On Chinese Medicine Solamargine pharmaceutical composition for killing cancer cells
US20020037855A1 (en) * 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
ATE526019T1 (de) * 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
NZ526169A (en) * 2000-10-31 2005-12-23 Boehringer Ingelheim Pharma Oral dosage self-emulsifying formulations of pyranone protease inhibitors
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
JP4213472B2 (ja) * 2001-03-30 2009-01-21 アメリカ合衆国 ゲルダナマイシン誘導体及びそれを用いる癌の治療方法
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
PT1435910E (pt) * 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina
CA2471081A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
HUP0402451A3 (en) * 2001-12-19 2008-04-28 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Also Published As

Publication number Publication date
EP1744743A2 (en) 2007-01-24
RU2006143666A (ru) 2008-06-20
RU2382643C2 (ru) 2010-02-27
JP2007537258A (ja) 2007-12-20
MXPA06012935A (es) 2007-01-26
WO2005110398A2 (en) 2005-11-24
BRPI0511036A (pt) 2007-11-27
US20050256097A1 (en) 2005-11-17
AU2005244115A1 (en) 2005-11-24
CA2565583A1 (en) 2005-11-24
WO2005110398A3 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
IL178689A0 (en) Pharmaceutical solution formulations containing 17-aag
EG27104A (en) Pharmaceutical compounds
IL177566A0 (en) Pharmaceutical formulations
IL182614A0 (en) Pharmaceutical compounds
GB0315657D0 (en) Pharmaceutical compounds
GB0426301D0 (en) Pharmaceutical formulations
GB0300427D0 (en) Pharmaceutical composition
GB0308511D0 (en) Pharmaceutical compounds
IL181229A0 (en) Noncardiotoxic pharmaceutical compounds
EP1699458A4 (en) PHARMACEUTICAL COMPOSITION
GB0416397D0 (en) Pharmaceutical formulations
GB0317315D0 (en) Pharmaceutical compounds
IL177351A0 (en) Pharmaceutical compositions containing cardiovascular drugs
GB0423800D0 (en) New pharmaceutical formulations
GB0313766D0 (en) Pharmaceutical compounds
GB0300885D0 (en) Pharmaceutical composition
GB0301736D0 (en) Pharmaceutical compounds
EP1853238A4 (en) PHARMACEUTICAL FORMULATIONS WITH 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN
GB0424742D0 (en) Pharmaceutical compounds
GB0306933D0 (en) Pharmaceutical composition
GB0428554D0 (en) Pharmaceutical compounds
GB0329617D0 (en) Pharmaceutical compounds
GB0307862D0 (en) Pharmaceutical composition
GB0408076D0 (en) Pharmaceutical formulations
GB0428010D0 (en) Pharmaceutical formulations